HomeComparePTKFY vs EQR

PTKFY vs EQR: Dividend Comparison 2026

PTKFY yields 4.06% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $6.2K in total portfolio value
10 years
PTKFY
PTKFY
● Live price
4.06%
Share price
$10.88
Annual div
$0.44
5Y div CAGR
19.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.6K
Annual income
$4,502.78
Full PTKFY calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — PTKFY vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTKFYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTKFY + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTKFY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTKFY
Annual income on $10K today (after 15% tax)
$345.04/yr
After 10yr DRIP, annual income (after tax)
$3,827.36/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $826.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTKFY + EQR for your $10,000?

PTKFY: 50%EQR: 50%
100% EQR50/50100% PTKFY
Portfolio after 10yr
$44.7K
Annual income
$4,989.19/yr
Blended yield
11.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PTKFY
No analyst data
Altman Z
3.3
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTKFY buys
0
EQR buys
0
No recent congressional trades found for PTKFY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTKFYEQR
Forward yield4.06%5.87%
Annual dividend / share$0.44$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR19.4%15.8%
Portfolio after 10y$41.6K$47.8K
Annual income after 10y$4,502.78$5,475.61
Total dividends collected$18.1K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PTKFY vs EQR ($10,000, DRIP)

YearPTKFY PortfolioPTKFY Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,185$484.68$11,380$679.82$195.00EQR
2$12,573$604.92$13,014$837.25$441.00EQR
3$14,211$758.78$14,961$1,036.20$750.00EQR
4$16,163$957.09$17,297$1,289.22$1.1KEQR
5$18,509$1,214.69$20,121$1,613.15$1.6KEQR
6$21,357$1,552.20$23,561$2,030.84$2.2KEQR
7$24,851$1,998.58$27,783$2,573.54$2.9KEQR
8$29,185$2,595.01$33,013$3,284.39$3.8KEQR
9$34,629$3,400.82$39,547$4,223.51$4.9KEQR
10$41,556$4,502.78$47,791$5,475.61$6.2KEQR

PTKFY vs EQR: Complete Analysis 2026

PTKFYStock

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Full PTKFY Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PTKFY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTKFY vs SCHDPTKFY vs JEPIPTKFY vs OPTKFY vs KOPTKFY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.